North America & Europe Epilepsy Market Research Report Information Forecast to 2032
By Condition (Generalized Epilepsy And Focal Epilepsy), By diagnosis & treatment, By End User (hospitals & clinics, diagnostic centers, and others), By Region (US, Canada, Europe)
Market Overview
It is expected that the North America and Europe Epilepsy Market will experience a robust market growth rate of 8.18% during the review period. Epilepsy is a chronic neurological condition that results in recurrent seizures and effects the brain. Seizures are episodes of uncontrolled electrical activity in the brain that can result in alterations in sensation, movement, consciousness, and behavior.
The North American and European epilepsy market is being driven by the growing awareness and understanding of epilepsy, as well as the increasing incidences of epilepsy in these regions. Nevertheless, the epilepsy market in North America and Europe is anticipated to be constrained by the adverse effects of antiepileptic drugs. However, it is anticipated that the market will generate lucrative opportunities as a result of the growing number of clinical trials for epilepsy diagnosis products and the increased investment in epilepsy diagnosis and treatment research.
Market Segmentation
The epilepsy market in North America and Europe has been segmented into generalized epilepsy and focal epilepsy, as determined by the condition.
The North American and European epilepsy market has been segmented into diagnosis and treatment.
The market has been segmented into hospitals & clinics, diagnostic centers, and others based on the end consumer.
In 2022, the North American epilepsy market was valued at USD 6,888.72 million and is anticipated to register a compound annual growth rate (CAGR) of 7.88% throughout the forecast period. The United States and Canada are the two additional segments of North America.
Major Players
Sun Pharmaceutical Industries Ltd, Johnson & Johnson Services, Inc, Novartis AG, GlaxoSmithKline, Boston Scientific Corporation, Abbott, Cipla ltd., UCB S. A, H. Lundbeck A/S, and Eisai Co., Ltd. are key market participants.
圖表清單 List of Tables & Figures
LIST OF TABLES
TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT 33
TABLE 2 R&D INVESTMENT BY MAJOR PHARMACEUTICAL AND MEDICAL DEVICE COMPANIES ON EPILEPSY 45
TABLE 3 LIST OF FAILED CLINICAL TRIALS FOR EPILEPSY DRUG 45
TABLE 4 NORTH AMERICA AND EUROPE EPILEPSY MARKET, BY CONDITION, 2019–2032 (USD MILLION) 51
TABLE 5 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR GENERALIZED EPILEPSY, BY REGION, 2019–2032 (USD MILLION) 52
TABLE 6 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR FOCAL EPILEPSY, BY REGION, 2019–2032 (USD MILLION) 52
TABLE 7 NORTH AMERICA AND EUROPE EPILEPSY MARKET, DIAGNOSIS & TREATMENT SEGMENT ATTRACTIVENESS, 2022-2032 (USD MILLION) 53
TABLE 8 NORTH AMERICA AND EUROPE EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2019–2032 (USD MILLION) 54
TABLE 9 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR DIAGNOSIS, BY REGION, 2019–2032 (USD MILLION) 55
TABLE 10 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE, 2019–2032 (USD MILLION) 55
TABLE 11 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR BLOOD TESTS, BY REGION, 2019–2032 (USD MILLION) 56
TABLE 12 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR ELECTROENCEPHALOGRAM (EEG) IMAGING TEST, BY REGION, 2019–2032 (USD MILLION) 56
TABLE 13 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR IMAGING SCAN, BY REGION, 2019–2032 (USD MILLION) 56
TABLE 14 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR IMAGING SCAN, BY TYPE, 2019–2032 (USD MILLION) 57
TABLE 15 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR MAGNETIC RESONANCE IMAGING (MRI) SCAN, BY REGION, 2019–2032 (USD MILLION) 57
TABLE 16 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR COMPUTERIZED TOMOGRAPHY (CT) SCAN, BY REGION, 2019–2032 (USD MILLION) 57
TABLE 17 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR OTHERS, BY REGION, 2019–2032 (USD MILLION) 58
TABLE 18 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR TREATMENT, BY REGION, 2019–2032 (USD MILLION) 58
TABLE 19 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR TREATMENT, BY TYPE, 2019–2032 (USD MILLION) 58
TABLE 20 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR DRUG CLASS, BY REGION, 2019–2032 (USD MILLION) 59
TABLE 21 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR DRUG CLASS, BY TYPE, 2019–2032 (USD MILLION) 59
TABLE 22 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR FIRST GENERATION ANTI-EPILEPTIC DRUGS, BY REGION, 2019–2032 (USD MILLION) 59
TABLE 23 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR SECOND GENERATION ANTI-EPILEPTIC DRUGS, BY REGION, 2019–2032 (USD MILLION) 60
TABLE 24 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR THIRD GENERATION ANTI-EPILEPTIC DRUGS, BY REGION, 2019–2032 (USD MILLION) 60
TABLE 25 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR SURGERY, BY REGION, 2019–2032 (USD MILLION) 60
TABLE 26 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR SURGERY, BY TYPE, 2019–2032 (USD MILLION) 61
TABLE 27 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR FOCAL RESECTION, BY REGION, 2019–2032 (USD MILLION) 61
TABLE 28 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR LESIONECTOMY, BY REGION, 2019–2032 (USD MILLION) 61
TABLE 29 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR CORPUS CALLOSOTOMY, BY REGION, 2019–2032 (USD MILLION) 62
TABLE 30 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR OTHERS, BY REGION, 2019–2032 (USD MILLION) 62
TABLE 31 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR THERAPIES, BY REGION, 2019–2032 (USD MILLION) 62
TABLE 32 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR THERAPIES, BY TYPE, 2019–2032 (USD MILLION) 63
TABLE 33 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR VAGUS NERVE STIMULATION, BY REGION, 2019–2032 (USD MILLION) 63
TABLE 34 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR DEEP BRAIN STIMULATION, BY REGION, 2019–2032 (USD MILLION) 63
TABLE 35 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR RESPONSIVE NEUROSTIMULATION, BY REGION, 2019–2032 (USD MILLION) 64
TABLE 36 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR THERMOCOAGULATION, BY REGION, 2019–2032 (USD MILLION) 64
TABLE 37 NORTH AMERICA AND EUROPE EPILEPSY MARKET, BY END USER, 2019–2032 (USD MILLION) 66
TABLE 38 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR HOSPITALS AND CLINICS, BY REGION, 2019–2032 (USD MILLION) 67
TABLE 39 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR DIAGNOSTIC CENTERS, BY REGION, 2019–2032 (USD MILLION) 67
TABLE 40 NORTH AMERICA AND EUROPE EPILEPSY MARKET, FOR OTHERS, BY REGION, 2019–2032 (USD MILLION) 68
TABLE 41 NORTH AMERICA: EPILEPSY MARKET, BY COUNTRY, 2019–2032 (USD MILLION) 70
TABLE 42 NORTH AMERICA: EPILEPSY MARKET, BY CONDITION, 2019–2032 (USD MILLION) 71
TABLE 43 NORTH AMERICA: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MILLION) 71
TABLE 44 NORTH AMERICA: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE, 2019-2032 (USD MILLION) 71
TABLE 45 NORTH AMERICA: EPILEPSY MARKET, FOR IMAGING SCAN, BY TYPE, 2019–2032 (USD MILLION) 72
TABLE 46 NORTH AMERICA: EPILEPSY MARKET, FOR TREATMENT, BY TYPE, 2019–2032 (USD MILLION) 72
TABLE 47 NORTH AMERICA: EPILEPSY MARKET, FOR DRUG CLASS, BY TYPE, 2019–2032 (USD MILLION) 72
TABLE 48 NORTH AMERICA: EPILEPSY MARKET, FOR SURGERY, BY TYPE, 2019–2032 (USD MILLION) 73
TABLE 49 NORTH AMERICA: EPILEPSY MARKET, FOR THERAPIES, BY TYPE, 2019–2032 (USD MILLION) 73
TABLE 50 NORTH AMERICA: EPILEPSY MARKET, BY END USER, 2019–2032 (USD MILLION) 73
TABLE 51 US: EPILEPSY MARKET, BY CONDITION, 2019–2032 (USD MILLION) 74
TABLE 52 US: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MILLION) 74
TABLE 53 US: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE, 2019-2032 (USD MILLION) 74
TABLE 54 US: EPILEPSY MARKET, FOR IMAGING SCAN, BY TYPE, 2019–2032 (USD MILLION) 75
TABLE 55 US: EPILEPSY MARKET, FOR TREATMENT, BY TYPE, 2019–2032 (USD MILLION) 75
TABLE 56 US: EPILEPSY MARKET, FOR DRUG CLASS, BY TYPE, 2019–2032 (USD MILLION) 75
TABLE 57 US: EPILEPSY MARKET, FOR SURGERY, BY TYPE, 2019–2032 (USD MILLION) 76
TABLE 58 US: EPILEPSY MARKET, FOR THERAPIES, BY TYPE, 2019–2032 (USD MILLION) 76
TABLE 59 US: EPILEPSY MARKET, BY END USER, 2019–2032 (USD MILLION) 76
TABLE 60 CANADA: EPILEPSY MARKET, BY CONDITION, 2019–2032 (USD MILLION) 77
TABLE 61 CANADA: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MILLION) 77
TABLE 62 CANADA: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE, 2019-2032 (USD MILLION) 77
TABLE 63 CANADA: EPILEPSY MARKET, FOR IMAGING SCAN, BY TYPE, 2019–2032 (USD MILLION) 78
TABLE 64 CANADA: EPILEPSY MARKET, FOR TREATMENT, BY TYPE, 2019–2032 (USD MILLION) 78
TABLE 65 CANADA: EPILEPSY MARKET, FOR DRUG CLASS, BY TYPE, 2019–2032 (USD MILLION) 78
TABLE 66 CANADA: EPILEPSY MARKET, FOR SURGERY, BY TYPE, 2019–2032 (USD MILLION) 79
TABLE 67 CANADA: EPILEPSY MARKET, FOR THERAPIES, BY TYPE, 2019–2032 (USD MILLION) 79
TABLE 68 CANADA: EPILEPSY MARKET, BY END USER, 2019–2032 (USD MILLION) 79
TABLE 69 EUROPE EPILEPSY MARKET, BY COUNTRY, 2019–2032 (USD MILLION) 81
TABLE 70 EUROPE EPILEPSY MARKET, BY CONDITION, 2019–2032 (USD MILLION) 81
TABLE 71 EUROPE EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2019–2032 (USD MILLION) 82
TABLE 72 EUROPE EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE, 2019–2032 (USD MILLION) 82
TABLE 73 EUROPE EPILEPSY MARKET, FOR IMAGING SCAN, BY TYPE, 2019–2032 (VOLUME) 82
TABLE 74 EUROPE EPILEPSY MARKET, FOR TREATMENT, BY TYPE, 2019–2032 (USD MILLION) 83
TABLE 75 EUROPE EPILEPSY MARKET, FOR DRUG CLASS, BY TYPE, 2019–2032 (USD MILLION) 83
TABLE 76 EUROPE EPILEPSY MARKET, FOR SURGERY, BY TYPE, 2019–2032 (USD MILLION) 83
TABLE 77 EUROPE EPILEPSY MARKET, FOR THERAPIES, BY TYPE, 2019–2032 (USD MILLION) 84
TABLE 78 EUROPE EPILEPSY MARKET, BY END USER, 2019–2032 (USD MILLION) 84
TABLE 79 GERMANY EPILEPSY MARKET, BY CONDITION, 2019–2032 (USD MILLION) 84
TABLE 80 GERMANY EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2019–2032 (USD MILLION) 85
TABLE 81 GERMANY EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE, 2019–2032 (USD MILLION) 85
TABLE 82 GERMANY EPILEPSY MARKET, FOR IMAGING SCAN, BY TYPE, 2019–2032 (VOLUME) 85
TABLE 83 GERMANY EPILEPSY MARKET, FOR TREATMENT, BY TYPE, 2019–2032 (USD MILLION) 86
TABLE 84 GERMANY EPILEPSY MARKET, FOR DRUG CLASS, BY TYPE, 2019–2032 (USD MILLION) 86
TABLE 85 GERMANY EPILEPSY MARKET, FOR SURGERY, BY TYPE, 2019–2032 (USD MILLION) 86
TABLE 86 GERMANY EPILEPSY MARKET, FOR THERAPIES, BY TYPE, 2019–2032 (USD MILLION) 87
TABLE 87 GERMANY EPILEPSY MARKET, BY END USER, 2019–2032 (USD MILLION) 87
TABLE 88 FRANCE EPILEPSY MARKET, BY CONDITION, 2019–2032 (USD MILLION) 87
TABLE 89 FRANCE EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2019–2032 (USD MILLION) 88
TABLE 90 FRANCE EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE, 2019–2032 (USD MILLION) 88
TABLE 91 FRANCE EPILEPSY MARKET, FOR IMAGING SCAN, BY TYPE, 2019–2032 (VOLUME) 88
TABLE 92 FRANCE EPILEPSY MARKET, FOR TREATMENT, BY TYPE, 2019–2032 (USD MILLION) 89
TABLE 93 FRANCE EPILEPSY MARKET, FOR DRUG CLASS, BY TYPE, 2019–2032 (USD MILLION) 89
TABLE 94 FRANCE EPILEPSY MARKET, FOR SURGERY, BY TYPE, 2019–2032 (USD MILLION) 89
TABLE 95 FRANCE EPILEPSY MARKET, FOR THERAPIES, BY TYPE, 2019–2032 (USD MILLION) 90
TABLE 96 FRANCE EPILEPSY MARKET, BY END USER, 2019–2032 (USD MILLION) 90
TABLE 97 UK EPILEPSY MARKET, BY CONDITION, 2019–2032 (USD MILLION) 90
TABLE 98 UK EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2019–2032 (USD MILLION) 91
TABLE 99 UK EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE, 2019–2032 (USD MILLION) 91
TABLE 100 UK EPILEPSY MARKET, FOR IMAGING SCAN, BY TYPE, 2019–2032 (VOLUME) 91
TABLE 101 UK EPILEPSY MARKET, FOR TREATMENT, BY TYPE, 2019–2032 (USD MILLION) 92
TABLE 102 UK EPILEPSY MARKET, FOR DRUG CLASS, BY TYPE, 2019–2032 (USD MILLION) 92
TABLE 103 UK EPILEPSY MARKET, FOR SURGERY, BY TYPE, 2019–2032 (USD MILLION) 92
TABLE 104 UK EPILEPSY MARKET, FOR THERAPIES, BY TYPE, 2019–2032 (USD MILLION) 93
TABLE 105 UK EPILEPSY MARKET, BY END USER, 2019–2032 (USD MILLION) 93
TABLE 106 ITALY EPILEPSY MARKET, BY CONDITION, 2019–2032 (USD MILLION) 93
TABLE 107 ITALY EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2019–2032 (USD MILLION) 94
TABLE 108 ITALY EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE, 2019–2032 (USD MILLION) 94
TABLE 109 ITALY EPILEPSY MARKET, FOR IMAGING SCAN, BY TYPE, 2019–2032 (VOLUME) 94
TABLE 110 ITALY EPILEPSY MARKET, FOR TREATMENT, BY TYPE, 2019–2032 (USD MILLION) 95
TABLE 111 ITALY EPILEPSY MARKET, FOR DRUG CLASS, BY TYPE, 2019–2032 (USD MILLION) 95
TABLE 112 ITALY EPILEPSY MARKET, FOR SURGERY, BY TYPE, 2019–2032 (USD MILLION) 95
TABLE 113 ITALY EPILEPSY MARKET, FOR THERAPIES, BY TYPE, 2019–2032 (USD MILLION) 96
TABLE 114 ITALY EPILEPSY MARKET, BY END USER, 2019–2032 (USD MILLION) 96
TABLE 115 SPAIN EPILEPSY MARKET, BY CONDITION, 2019–2032 (USD MILLION) 96
TABLE 116 SPAIN EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2019–2032 (USD MILLION) 97
TABLE 117 SPAIN EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE, 2019–2032 (USD MILLION) 97
TABLE 118 SPAIN EPILEPSY MARKET, FOR IMAGING SCAN, BY TYPE, 2019–2032 (VOLUME) 97
TABLE 119 SPAIN EPILEPSY MARKET, FOR TREATMENT, BY TYPE, 2019–2032 (USD MILLION) 98
TABLE 120 SPAIN EPILEPSY MARKET, FOR DRUG CLASS, BY TYPE, 2019–2032 (USD MILLION) 98
TABLE 121 SPAIN EPILEPSY MARKET, FOR SURGERY, BY TYPE, 2019–2032 (USD MILLION) 98
TABLE 122 SPAIN EPILEPSY MARKET, FOR THERAPIES, BY TYPE, 2019–2032 (USD MILLION) 99
TABLE 123 SPAIN EPILEPSY MARKET, BY END USER, 2019–2032 (USD MILLION) 99
TABLE 124 REST OF EUROPE EPILEPSY MARKET, BY CONDITION, 2019–2032 (USD MILLION) 99
TABLE 125 REST OF EUROPE EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2019–2032 (USD MILLION) 100
TABLE 126 REST OF EUROPE EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE, 2019–2032 (USD MILLION) 100
TABLE 127 REST OF EUROPE EPILEPSY MARKET, FOR IMAGING SCAN, BY TYPE, 2019–2032 (VOLUME) 100
TABLE 128 REST OF EUROPE EPILEPSY MARKET, FOR TREATMENT, BY TYPE, 2019–2032 (USD MILLION) 101
TABLE 129 REST OF EUROPE EPILEPSY MARKET, FOR DRUG CLASS, BY TYPE, 2019–2032 (USD MILLION) 101
TABLE 130 REST OF EUROPE EPILEPSY MARKET, FOR SURGERY, BY TYPE, 2019–2032 (USD MILLION) 101
TABLE 131 REST OF EUROPE EPILEPSY MARKET, FOR THERAPIES, BY TYPE, 2019–2032 (USD MILLION) 102
TABLE 132 REST OF EUROPE EPILEPSY MARKET, BY END USER, 2019–2032 (USD MILLION) 102
TABLE 133 PUBLIC PLAYERS STOCK SUMMARY 106
TABLE 134 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL 106
TABLE 135 PRODUCT LAUNCH/ PRODUCT APPROVAL 107
TABLE 136 ACQUISITION 107
TABLE 137 JOHNSON & JOHNSON SERVICES, INC.: PRODUCTS OFFERED 109
TABLE 138 BOSTON SCIENTIFIC CORPORATION: PRODUCTS OFFERED 112
TABLE 139 BOSTON SCIENTIFIC CORPORATION: KEY DEVELOPMENTS 113
TABLE 140 ABBOTT: PRODUCTS OFFERED 116
TABLE 141 CIPLA LTD: PRODUCTS OFFERED 119
TABLE 142 UCB S.A: PRODUCT OFFERED 122
TABLE 143 UCB S.A: KEY DEVELOPMENTS 123
TABLE 144 H. LUNDBECK A/S: PRODUCT OFFERED 125
TABLE 145 EISAI CO., LTD: PRODUCT OFFERED 128
TABLE 146 NOVARTIS AG: PRODUCTS OFFERED 131
TABLE 147 GLAXOSMITHKLINE PLC: PRODCUTS OFFERED 134
TABLE 148 SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCTS OFFERED 137
LIST OF FIGURES
FIGURE 1 NORTH AMERICA AND EUROPE EPILEPSY MARKET: STRUCTURE 20
FIGURE 2 NORTH AMERICA AND EUROPE EPILEPSY MARKET: MARKET GROWTH FACTOR ANALYSIS (2022-2032) 37
FIGURE 3 DRIVER IMPACT ANALYSIS (2023-2032) 39
FIGURE 4 RESTRAINT IMPACT ANALYSIS (2022-2032) 40
FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: NORTH AMERICA AND EUROPE EPILEPSY MARKET 42
FIGURE 6 NORTH AMERICA AND EUROPE EPILEPSY MARKET, CONDITION SEGMENT ATTRACTIVENESS, 2022-2032 (USD MILLION) 50
FIGURE 7 NORTH AMERICA AND EUROPE EPILEPSY MARKET, BY CONDITION, 2022 & 2032 (USD MILLION) 51
FIGURE 8 NORTH AMERICA AND EUROPE EPILEPSY MARKET SHARE (%), BY CONDITION, 2022 52
FIGURE 9 NORTH AMERICA AND EUROPE EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2022 & 2032 (USD MILLION) 54
FIGURE 10 NORTH AMERICA AND EUROPE EPILEPSY MARKET SHARE (%), BY DIAGNOSIS & TREATMENT, 2022 55
FIGURE 11 NORTH AMERICA AND EUROPE EPILEPSY MARKET, END USER SEGMENT ATTRACTIVENESS, 2022-2032 (USD MILLION) 65
FIGURE 12 NORTH AMERICA AND EUROPE EPILEPSY MARKET, BY END USER, 2022 & 2032 (USD MILLION) 66
FIGURE 13 NORTH AMERICA AND EUROPE EPILEPSY MARKET SHARE (%), BY END USER, 2022 67
FIGURE 14 NORTH AMERICA MARKET ANALYSIS: EPILEPSY MARKET, 2019-2032 (USD MILLION) 69
FIGURE 15 NORTH AMERICA: EPILEPSY MARKET, BY COUNTRY, 2022 & 2032 (USD MILLION) 70
FIGURE 16 NORTH AMERICA: EPILEPSY MARKET SHARE (%), BY COUNTRY, 2022 70
FIGURE 17 EUROPE MARKET ANALYSIS: EPILEPSY MARKET, 2019-2032 (USD MILLION) 80
FIGURE 18 EUROPE EPILEPSY MARKET SHARE, BY COUNTRY, 2022 (% SHARE) 80
FIGURE 19 EUROPE EPILEPSY MARKET, BY COUNTRY, 2022 & 2032 (USD MILLION) 81
FIGURE 20 EPILEPSY MARKET PLAYERS: COMPETITIVE ANALSIS, 2022 104
FIGURE 21 COMPETITOR DASHBOARD: NORTH AMERICA & EUROPE EPILEPSY MARKET 105
FIGURE 22 JOHNSON & JOHNSON SERVICES, INC.: FINANCIAL OVERVIEW SNAPSHOT 109
FIGURE 23 JOHNSON & JOHNSON SERVICES, INC.: SWOT ANALYSIS 110
FIGURE 24 BOSTON SCIENTIFIC CORPORATION: FINANCIAL OVERVIEW SNAPSHOT 112
FIGURE 25 BOSTON SCIENTIFIC CORPORATION: SWOT ANALYSIS 113
FIGURE 26 ABBOTT: FINANCIAL OVERVIEW SNAPSHOT 116
FIGURE 27 ABBOTT: SWOT ANALYSIS 117
FIGURE 28 CIPLA LTD: FINANCIAL OVERVIEW 119
FIGURE 29 CIPLA LTD: SWOT ANALYSIS 120
FIGURE 30 UCB S.A: FINANCIAL OVERVIEW SNAPSHOT 122
FIGURE 31 H. LUNDBECK A/S: FINANCIAL OVERVIEW SNAPSHOT 125
FIGURE 32 EISAI CO., LTD: FINANCIAL OVERVIEW SNAPSHOT 128
FIGURE 33 NOVARTIS AG: FINANCIAL OVERVIEW 131
FIGURE 34 NOVARTIS AG: SWOT ANALYSIS 132
FIGURE 35 GLAXOSMITHKLINE PLC: FINANCIAL OVERVIEW 134
FIGURE 36 SUN PHARMACEUTICAL INDUSTRIES LTD.: FINANCIAL OVERVIEW 137
量子訊息有限公司為 Market Research Future 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們